Dongwha Pharm.Co.,Ltd (KRX:000020)
South Korea
· Delayed Price · Currency is KRW 6,260.00
+20.00 (0.32%)
Feb 21, 2025, 9:00 AM KST
Dongwha Pharm.Co.,Ltd Revenue
Dongwha Pharm.Co.,Ltd had revenue of 110.19B KRW in the quarter ending September 30, 2024, with 26.00% growth. This brings the company's revenue in the last twelve months to 428.48B, up 18.59% year-over-year. In the year 2023, Dongwha Pharm.Co.,Ltd had annual revenue of 361.11B with 6.08% growth.
Revenue (ttm)
428.48B
Revenue Growth
+18.59%
P/S Ratio
0.40
Revenue / Employee
525.10M
Employees
816
Market Cap
173.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 361.11B | 20.68B | 6.08% |
| Dec 31, 2022 | 340.43B | 47.41B | 16.18% |
| Dec 31, 2021 | 293.02B | 20.94B | 7.70% |
| Dec 31, 2020 | 272.08B | -35.07B | -11.42% |
| Dec 31, 2019 | 307.15B | 547.44M | 0.18% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,364.39B |
| Celltrion | 2,876.25B |
| Yuhan | 2,008.84B |
| SK Biopharmaceuticals | 511.33B |
| SK bioscience | 201.30B |
| Hanmi Pharm. | 1,495.50B |
| Hanmi Science | 1,283.65B |
| Hanall Biopharma | 134.24B |